Femasys, Inc. (FEMY)
|Net Income (ttm)||-6.54M|
|Trading Day||June 22|
|Day's Range||9.71 - 11.15|
|52-Week Range||9.71 - 13.75|
NEW YORK, June 21, 2021 /PRNewswire/ -- Chardan, a global investment bank, today announced that it acted as lead left bookrunner in the successful closing of the $34.45 million IPO of Femasys, Inc. (NAS...
Femasys Inc., a biomedical company focused on transforming women's healthcare by developing novel solutions...
Femasys, Inc. has filed to go public with an IPO on the NASDAQ.
Femasys is a biomedical company focused on transforming women’s healthcare by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. As a woman-founded and led company with an expansive, internally created intellectual property portfolio with over 100 patents globally, in-house chemistry, manufacturing and controls, or CMC, and device manufacturing capabilities and proven ability to develop and commercialize products, we believe that we are well-positioned to be... [Read more...]
Surgical & Medical Instruments & Apparatus
|IPO Date |
Jun 18, 2021
|Stock Exchange |
|Ticker Symbol |
In 2020, Femasys's revenue was $1.04 million, an increase of 11.72% compared to the previous year's $929,064. Losses were -$6.91 million, -38.65% less than in 2019.